Loading patent…
AssigneeCancer Research Campaign Technology Limited
InventorsDAVID LANE, VOLKER BOTTGER, ANGELIKA BOTTGER, STEVEN MICHAEL PICKSLEY, HEINZ-KURT HOCHKEPPEL, CARLOS GARCIA-ECHEVERRIA, PATRICK CHENE, PASCAL FURET
Estimating the term…
The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounsa, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild typr p53 suppressor by interfering with the interaction between human p53 and human MDM2.
A compound or a derivative thereof, capable of binding to MDM2, particularly human DM2, and specifically inhibiting or blocking the binding of MDM2 to the p53 protein, particularly human p53, in vitro or in vivo.
A method for inducing growth arrest or apoptosis in tumor cells which contain wild type p53 and non-elevated MDM2 levels comprising inhibiting the interaction between MDM2 and p53 in vivos or in vitro.
A method of treating or preventing a hyperproliferative disease comprising tumor cells having wild type p53 and a non-elevated MDM2 level, the method comprising interfering with the interaction of human p53 and human MDM2.
Dependencies are inferred from the claim text.